[ATHX] Athersys, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.58 Change: 0.04 (2.6%)
Ext. hours: Change: 0 (0%)

chart ATHX

Refresh chart

Strongest Trends Summary For ATHX

ATHX is in the long-term down -33% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company?s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic

Fundamental Ratios
Shares Outstanding EPS-0.3 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 88.4% Sales Growth - Q/Q211.06% P/E-4.73
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-57.43% ROE-121.38% ROI
Current Ratio2.74 Quick Ratio Long Term Debt/Equity Debt Ratio0.74
Gross Margin Operating Margin-1731.39% Net Profit Margin-1401.34% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities8.32 M Cash From Investing Activities-60 K Cash From Operating Activities1.12 M Gross Profit
Net Profit-12.48 M Operating Profit-6.89 M Total Assets40.19 M Total Current Assets38.73 M
Total Current Liabilities14.15 M Total Debt180 K Total Liabilities21.18 M Total Revenue730 K
Technical Data
High 52 week2.08 Low 52 week1.21 Last close1.42 Last change0%
RSI71.88 Average true range0.06 Beta0.54 Volume397.95 K
Simple moving average 20 days6.77% Simple moving average 50 days4.43% Simple moving average 200 days-4.84%
Performance Data
Performance Week4.41% Performance Month5.19% Performance Quart5.97% Performance Half-23.66%
Performance Year-26.04% Performance Year-to-date-1.39% Volatility daily1.78% Volatility weekly3.97%
Volatility monthly8.14% Volatility yearly28.18% Relative Volume350.71% Average Volume477.56 K
New High New Low


2020-05-18 06:00:00 | Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference

2020-05-09 22:01:03 | Athersys ATHX Q1 2020 Earnings Call Transcript

2020-05-08 19:35:13 | Edited Transcript of ATHX earnings conference call or presentation 7-May-20 8:30pm GMT

2020-05-07 16:05:00 | Athersys Reports First Quarter 2020 Results

2020-05-07 16:00:07 | Dawson James Sticks to Their Buy Rating for Athersys

2020-05-07 13:44:51 | Exclusive: U.S. companies got emergency government loans despite having months of cash

2020-05-06 14:32:57 | Analyst Believes Potential COVID-19 Treatment Can Push Ahersys ATHX Stock up to $12

2020-05-05 06:00:00 | Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS

2020-05-04 11:19:00 | Here's Why Athersys Tumbled 23.3% in April

2020-05-04 11:19:00 | Here's Why Athersys Tumbled 23.3% in April

2020-05-01 06:00:00 | Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS

2020-04-29 14:47:00 | Athersys to Present at the Bank of America Merrill Lynch Virtual Healthcare Conference on May 14

2020-04-28 06:40:00 | Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?

2020-04-22 00:00:55 | The Notorious PPP

2020-04-21 08:00:00 | Athersys to Host First Quarter Financial Results Call

2020-04-20 16:05:00 | Athersys Announces Closing of Public Offering of Common Stock

2020-04-15 21:33:00 | Athersys Announces Pricing of Public Offering of Common Stock

2020-04-15 16:27:00 | Athersys Announces Proposed Public Offering of Common Stock

2020-04-15 11:47:00 | FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients

2020-04-15 08:03:02 | The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US

2020-04-14 08:37:12 | Will Stem Cell Therapies Aid in Fight Against Coronavirus?

2020-04-13 09:54:12 | Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics

2020-04-13 08:03:38 | Athersys Jumps More Than 20% After FDA Approves MultiStem Coronavirus Study

2020-04-13 06:14:00 | Athersys's stock shoots up after FDA OKs study for COVID-19-induced respiratory distress treatment

2020-04-13 06:00:00 | FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome

2020-04-01 16:22:04 | Edited Transcript of ATHX earnings conference call or presentation 16-Mar-20 8:30pm GMT

2020-03-30 06:00:00 | HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares

2020-03-26 10:15:43 | Here's Why We're Watching Athersys's NASDAQ:ATHX Cash Burn Situation

2020-03-19 06:00:00 | Athersys Names Maia Hansen Senior Vice President, Operations and Supply Chain

2020-03-16 16:05:00 | Athersys Announces Financial Results for Fourth Quarter and Full Year 2019

2020-03-16 14:30:00 | Athersys, Inc. to Host Earnings Call

2020-03-09 09:58:17 | Needham: 3 Stocks to Count on If the Coronavirus Crisis Continues

2020-02-10 08:00:00 | Athersys to Host Year-End 2019 Financial Results Call

2020-02-03 06:00:00 | Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635c4

2020-01-24 05:36:13 | How Much Did Athersys, Inc.'s NASDAQ:ATHX CEO Pocket Last Year?

2020-01-15 08:22:46 | The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

2020-01-15 06:00:10 | Athersys Names Ivor Macleod Chief Financial Officer

2020-01-14 06:00:10 | Athersys Provides Update on One-Year ARDS Study Data

2019-12-19 16:56:56 | Hedge Funds Staying Clear Of Athersys, Inc. NASDAQ:ATHX

2019-11-21 19:16:50 | Edited Transcript of ATHX earnings conference call or presentation 6-Nov-19 9:30pm GMT

2019-11-14 06:00:00 | Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program

2019-11-11 09:30:31 | Were Hedge Funds Right About Souring On Athersys, Inc. ATHX?

2019-11-06 16:05:00 | Athersys Reports Third Quarter 2019 Results

2019-11-03 07:47:49 | Did You Manage To Avoid Athersys's NASDAQ:ATHX 36% Share Price Drop?

2019-10-14 13:00:00 | Athersys to Host Third Quarter Financial Results Call

2019-09-25 08:00:00 | Athersys to Present at 2019 Cell & Gene Meeting on the Mesa

2019-09-19 08:37:38 | Athersys, Inc. NASDAQ:ATHX: Is It Growing Too Fast?

2019-09-05 11:22:17 | Edited Transcript of ATHX earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-08 11:23:58 | Athersys ATHX Q2 2019 Earnings Call Transcript

2019-08-07 16:05:00 | Athersys Reports Second Quarter 2019 Results